320.1K XNAS Volume
XNAS 28 Mar, 2025 5:30 PM (EDT)
Acelyrin Inc Key Metrics
Default
Market Capitalization | 261.8 |
PE TTM | -1.1 |
Price to Book | 0.5 |
Institutional holding current Qtr % | 80.3 |
Net Profit Qtr Growth YoY % | 17 |
Net Profit TTM Growth % | 35 |
Piotroski Score | 2 |
Rel Perf vs Sector quarter% | -24.8 |
All financials are in USD Million and price data in USD
VIEW MORE
Not Eligible
Expensive Valuation
Technically Bearish
Check Before You Buy
VIEW FULL CHECKLISTLow rank
4Positive12Negative
25.0% Pass in checklist
Check P/E Buy Sell Zone
This stock has negative PE
Acelyrin Inc Stock Price Analysis
Day Price Range | 2.6 (LTP) 2.62.6 LowHigh |
Week Price Range | 2.6 (LTP) 2.42.8 LowHigh |
Month Price Range | 2.6 (LTP) 2.32.9 LowHigh |
52 Week Price Range | 2.6 (LTP) 1.87.2 LowHigh |
Acelyrin Inc Live Price Chart
Switch to TradingView
Revenue forecast
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get Acelyrin Inc Stock Analysis
Acelyrin Inc stock analysis with key metrics, changes, and trends.
Acelyrin Inc Metric | VALUE | CHANGE % | TREND | ANALYSIS | |
---|---|---|---|---|---|
Annual Net Profit | $248.23 M | 34.96% | positive |
| |
Price to Earning Ratio | -1.05 | - | negative |
| |
Stock Price | $2.60 | -61.48% | negative |
| |
Quarterly Net profit | $79.03 M | 16.99% | positive |
| |
Mutual Fund Holding | 35.97 % | -1.04% | negative |
| |
Institutional Holding | 80.35 % | 0% | neutral |
|
Loading data..
Acelyrin Inc - Company Profile
What does Acelyrin Inc do?
Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
Acelyrin Inc Management structure
All Gross Remunerations are in USD
Acelyrin Inc Board of directors
All Gross Remunerations are in USD